organic molecular entity goserelin http://purl.bioontology.org/ontology/MESH/D017273 http://purl.bioontology.org/ontology/SNOMEDCT/108771008 http://purl.obolibrary.org/obo/CHEBI_5523 http://purl.obolibrary.org/obo/NCIT_C1374 https://en.wikipedia.org/wiki/Goserelin https://www.wikidata.org/wiki/Q1992653 L02AE03 A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females). Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. A synthetic long-acting agonist of gonadotropin-releasing hormone. Goserelin is used in treatments of malignant neoplasms of the prostate, uterine fibromas, and metastatic breast cancer. gonadotropin-releasing hormone analog